Sana Biotechnology, Inc. develops engineered cells as medicines for patients, with programs that apply cell engineering, hypoimmune platform technology, and fusogen-based delivery. News about SANA commonly covers its type 1 diabetes cell-replacement work, including UP421 and SC451, and its in vivo CAR T program SG293 for CD19-directed therapy in B-cell cancers and B-cell-mediated autoimmune diseases.
Company updates also include preclinical and clinical data presentations, research collaborations, manufacturing and regulatory preparation, financial results, equity financing activity, executive appointments, and investor conference presentations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.